**Specifications** table {#s0005}
========================

Subject area*Biology*More specific subject area*Inborn errors of metabolism*Type of data*Text files, tables, figures*How data was acquired*Clinical evaluations, magnetic resonance imaging, nerve conduction studies, spirography, lumbar spinal puncture*Data format*Raw, processed*Experimental factors*Subjects were treated with intrathecal laronidase, and pre- and post-treatment data are presented*Experimental features*Clinical data are presented descriptively. Adverse events were tabulated based on subject reporting. Magnetic resonance imaging data were scored for spinal cord compression, hydrocephalus, white matter hyperintensities, and cystic or cribriform changes. Pulmonary function tests, cerebrospinal fluid opening pressure and somatosensory evoked potentials were obtained in standard clinical fashion.*Data source location*N/A (multicenter clinical trial)*Data accessibility*N/A*

Value of the data {#s0010}
=================

•There are very few clinical data reports of cervical spinal stenosis due to mucopolysaccharidosis type I, or attempts at treatment.•Quantitative as well as qualitative data are presented.•The data may inform future studies of intrathecal enzyme replacement therapy for lysosomal storage disorders.

1. Experimental design, materials and methods {#s0015}
=============================================

1.1. Subjects {#s0020}
-------------

Study subjects are narratively described in data file 1. They were treated with intrathecal laronidase as described in Ref. [@bib1].

1.2. Measures of safety {#s0025}
-----------------------

To evaluate possible adverse effects of study treatments, participants had physical and neurologic examination before and after each study treatment. All new physical complaints were evaluated and recorded including their severity and attribution to study treatments. [Table 1](#t0005){ref-type="table"} lists nonserious adverse events.

1.3. Objective measures of efficacy {#s0030}
-----------------------------------

Response to treatment was assessed using a combination of subjective and objective measures. We evaluated somatosensory evoked potentials in the upper and lower extremity as per [@bib2]. Results are shown in [Table 2](#t0010){ref-type="table"}. MRI of brain and spinal cord were obtained to assess degree of cord compression and measurement of meningeal thickness was taken. MRI were performed using a 1.5-Tesla GE LX9.1. Brain imaging included sagittal T1-weighted, axial FLAIR, axial T2-weighted and axial diffusion-weighted images. Sagittal T1- and T2-weighted images of the whole spine and axial T1-weighted images of the cervical spine were obtained. Axial T1-weighted studies of the cervical spine were used to score spinal cord compression according to the methods of Houten and Cooper [@bib3]. Brain images were evaluated for abnormal signal intensity in T2, enlargement of perivascular spaces, and ventricular size as per Matheus et al. [@bib4]. Results are shown in [Tables 3--7](#t0015 t0020 t0025 t0030 t0035){ref-type="table"}. Subjects enrolled in the extension study also underwent pulmonary function testing using spirometry ([Fig. 1](#f0005){ref-type="fig"}). Cerebrospinal fluid glycosaminoglycans were measured at Seattle Children׳s Hospital using a clinically-available test ([Fig. 2](#f0010){ref-type="fig"}). The laboratory uses a dimethylene blue dye-binding assay to quantitate total glycosaminoglycans [@bib5]. Functional Independence Measure (FIM) score and Japanese Orthopedic Association (JOA) score measures were used to assess any changes in functional status and myelopathy. Results are shown in [Fig. 1](#f0005){ref-type="fig"} of Ref. [@bib1]. Scoring criteria for JOA and FIM are given in data files 2 and 3. The grading systems that were used to indicate the severity of spinal cord compression and brain imaging findings are given in data file 4.

Appendix A. Supporting information {#s0040}
==================================

Supplementary data

Supplementary data

Supplementary data

Supplementary data

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.08.004](http://dx.doi.org/10.1016/j.dib.2015.08.004){#ir0005}.

![Pulmonary function tests. Subjects in the extension study underwent pulmonary function tests by spirometry at each visit.](gr1){#f0005}

![CSF opening pressure. We measured opening pressure prior to each dose of intrathecal laronidase by manometry at the level of the right atrium. We did not obtain opening pressure measurements at Days 0 and 30 for subject 1 due to technical issues performing the lumbar puncture during those visits. Subjects 2--4 had a history of hydrocephalus and implanted CSF drainage shunts.](gr2){#f0010}

###### 

Nonserious adverse events.

  **Events occurring in \>1 study subject**   **Events occurring in 1 study subject**
  ------------------------------------------- ---------------------------------------------------------------------
  Headache                                    Anemia
  Neck pain                                   Nausea
  Hypoxemia                                   Pneumonia
  Desaturation during procedure               Tingling
  Elevated CSF opening pressure               Decreased sensation right hand
  Back pain                                   Blurred vision
  Myoclonic-like twitches                     Decreased visual acuity
  Diarrhea/gastroenteritis                    Weakness
  Upper respiratory infection                 Insomnia
  Fever                                       Elevated serum phosphorus
                                              Decreased serum protein
                                              Decreased serum albumin
                                              Elevated CSF protein
                                              Elevated CSF leukocyte count
                                              Hip and thigh pain
                                              Pruritus (with fentanyl)
                                              Pneumocephaly
                                              Dizziness
                                              Gradual turning outward of right foot hampering walking and balance
                                              Abdominal pain
                                              Clumsiness in leg
                                              Dyspnea and cough
                                              Joint Pain
                                              Hand cramps
                                              Perineal muscle cramps
                                              Tachycardia at rest
                                              Sore throat
                                              "Shaking while laying down"/"tremor"
                                              Abdominal cramping / dysmenorrhea
                                              Facial flushing
                                              Urinary urgency
                                              Influenza
                                              Leg weakness
                                              Urticaria
                                              Melena
                                              Malaise

CSF: cerebrospinal fluid.

###### 

Somatosensory evoked potentials. Intrasubject change (absolute) in latency (ms) during the pilot and extension studies for subjects with both baseline and end-study measurements.

  **4-Month pilot study**   **12-Month extension study**                                                                  
  ------------------------- ------------------------------------------ ------- ------------------------------------------ --------
  Median nerve                                                                                                            
  N9-N13A                   Absent                                     0.80    Absent                                     Absent
  N9-N13B                   Absent[a](#tbl2fna){ref-type="table-fn"}   −0.60   Absent                                     Absent
  N9-P13                    Absent                                     1.10    Absent                                     Absent
  N13A-N20                  Absent                                     −0.40   Absent[a](#tbl2fna){ref-type="table-fn"}   6.5
                                                                                                                          
  Posterior tibial nerve                                                                                                  
  N22-P30                   Absent                                     1.00    Absent                                     Absent
  N22-P40                   Absent                                     0.80    2.40                                       8.8

N9--N13B was present at baseline in subject 1 at a latency of 3.30 ms but absent at the Day 120 visit. N13A-N20 was present in subject 5 at the Day 120 visit at a latency of 10.8 ms but absent at baseline. Subject 2 did not have baseline measurements (the subject was not enrolled in the pilot study). Subject 4 did not have day 120 measurements (termination of participation due to subject death).

###### 

MRI cervical spinal cord compression (maximum grade).

  **4-Month pilot study**   **12-Month extension study**                        
  ------------------------- ------------------------------ -------- ----- ----- -----
  1                         3                              3        3     N/A   N/A
  2                         N/A                            N/A      3     3     N/A
  3                         2 to 3                         2 to 3   N/A   N/A   N/A
  4                         2                              N/A      N/A   N/A   N/A
  5                         1                              ND       1     2     2

Grading system: 0, 360° cushion of CSF around cord; 1, loss of CSF cushion w/o indentation of the cord but may have slight anterior cord flattening; 2, mild spinal cord compression; and 3, severe cord compression.

###### 

Brain MRI abnormal T2 signal intensity.

  **4-Month pilot study**   **12-Month extension study**                     
  ------------------------- ------------------------------ ----- ----- ----- -----
  1                         2                              2     2     N/A   N/A
  2                         N/A                            N/A   0     0     N/A
  3                         0                              0     N/A   N/A   N/A
  4                         2                              N/A   N/A   N/A   N/A
  5                         1                              1     1     2     2

Grading system: score signal changes on T2-weighted images as 0, absent; 1, patchy and confined to the periventricular area; 2, patchy but in other white matter areas as well as periventricular; and 3, diffuse.

###### 

Brain MRI enlargement of perivascular spaces.

  **4-Month pilot study**   **12-Month extension study**                     
  ------------------------- ------------------------------ ----- ----- ----- -----
  1                         2                              2     3     N/A   N/A
  2                         N/A                            N/A   1     1     N/A
  3                         0                              0     N/A   N/A   N/A
  4                         2                              N/A   N/A   N/A   N/A
  5                         3                              2     3     2     2

Grading system: 0, no enlargement; 1, \<3 mm enlargement; 2, between 3 and 8 mm enlargement; and 3, \>8 mm enlargement.

###### 

Brain MRI frontal-occipital horn ratio.

  **4-Month pilot study**   **12-Month extension study**                           
  ------------------------- ------------------------------ ------- ------- ------- -------
  1                         0.418                          0.406   0.368   N/A     N/A
  2                         N/A                            N/A     0.472   0.472   N/A
  3                         0.767                          0.752   N/A     N/A     N/A
  4                         0.547                          N/A     N/A     N/A     N/A
  5                         0.385                          0.385   0.385   0.588   0.598

FOR is calculated as follows: measure a ratio between the frontal and occipital horns of the lateral ventricle using the maximum distance between the outer borders of the frontal horns added to the distance between the outer borders of occipital horns, then divide by twice the maximum biparietal diameter.

###### 

Brain MRI atrophy and megacisterna magna.

  **4-Month pilot study**   **12-Month extension study**                     
  ------------------------- ------------------------------ ----- ----- ----- -----
  Brain atrophy                                                              
  1                         1                              1     1     N/A   N/A
  2                         N/A                            N/A   0     0     N/A
  3                         0                              0     N/A   N/A   N/A
  4                         0                              N/A   N/A   N/A   N/A
  5                         1                              1     1     1     1
                                                                             
  Megacisterna magna                                                         
  1                         1                              1     1     N/A   N/A
  2                         N/A                            N/A   1     1     N/A
  3                         1                              1     N/A   N/A   N/A
  4                         0                              N/A   N/A   N/A   N/A
  5                         0                              0     0     0     0

Grading system: 0, absent; 1, mild; 2, moderate; and 3, severe.
